Swissnex San Francisco
swissnex San Francisco is a key initiative of Switzerland’s State Secretariat for Education, Research and Innovation, operating as part of a global network that connects Switzerland with innovative hubs, including San Francisco. Established in 2004, it has over a decade of experience in fostering collaboration between Switzerland and North America through knowledge exchange. The organization serves as a platform for dialogue and networking in diverse fields such as science, education, art, and innovation, showcasing Swiss and North American creativity. Its activities are supported by a combination of public and private funding, with partnerships that strengthen its mission to facilitate connections in the San Francisco Bay Area, Silicon Valley, and beyond. Through its efforts, swissnex San Francisco plays a vital role in promoting collaboration and innovation in a rapidly evolving global landscape.
5 past transactions
Rea Diagnostics
Non Equity Assistance in 2023
Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.
Magnes
Non Equity Assistance in 2023
Magnes develops smart shoes equipped with advanced sensors to analyze walk patterns of individuals with neurological disorders. Its AI-powered system generates automatic reports and provides real-time gait feedback, enhancing clinical trial efficacy through data-driven therapy.
Suri Biotech
Non Equity Assistance in 2023
Suri Biotech is a biotechnology company specializing in the development of targeted bacterial strains aimed at alleviating bloating and intestinal discomfort. Its proprietary strains reduce hydrogen gas production by intestinal microorganisms, with potential applications in various functional gastrointestinal disorders.
MindMetrix
Non Equity Assistance in 2023
MindMetrix develops a mental training platform using eye-tracking-based neurofeedback technology. This platform connects neurophysiology with virtual reality for enhancing mental resilience, particularly among athletes aiming to optimize performance.
Cellestia
Non Equity Assistance in 2023
Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.